Trastuzumab (Herceptin) and HER2-positive breast cancer

CMAJ. Canadian Medical Association Journal

Volumn 174, Issue 1, 2006, Pages 36-37

  Murray, Sally ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

BREAST CANCER; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; EARLY CANCER; FEMALE; HUMAN; INFECTION; NOTE; RISK REDUCTION; SIDE EFFECT; TREATMENT OUTCOME; VASCULAR DISEASE;

EID: 30344478588     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.051452     Document Type: Note

References (3)

1. Romond EH, Perez EA, Bryant I, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2 positive breast cancer. N Engl J Med 2005;353(16):1673-84.
2. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 Study Group. J Clin Oncol 2005;23:4265-74.
3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.